MV Capital Management’s Royalty Pharma RPRX Stock Holding History

MV Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.04K	Buy	105 +1	+1%	+$44	﹤0.01%	619
2025 Q4	$4.02K	Hold	104	–	–	﹤0.01%	637
2025 Q3	$3.67K	Hold	104	–	–	﹤0.01%	639
2025 Q2	$3.75K	Buy	104 +47	+82%	+$1.56K	﹤0.01%	636
2025 Q1	$1.77K	Buy	57 +18	+46%	+$571	﹤0.01%	707
2024 Q4	$995	Buy	39 +27	+225%	+$716	﹤0.01%	751
2024 Q3	$340	Sell	12 -1	-8%	-$28	﹤0.01%	848
2024 Q2	$343	Buy	13 +8	+160%	+$222	﹤0.01%	757
2024 Q1	$152	Buy	5 +3	+150%	+$88	﹤0.01%	743
2023 Q4	$57	Buy	+2	New	+$55	﹤0.01%	746

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MV Capital Management's RPRX Position: Q1 2026 in Review

MV Capital Management increased its Royalty Pharma (RPRX) stake by 0.96% in Q1 2026, buying an estimated $44 and bringing the position to 105 shares worth $5.04K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

MV Capital Management first reported a position in RPRX in Q4 2023 and has held it in 10 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

MV Capital Management held 105 shares of Royalty Pharma worth $5.04K as of Q1 2026.
MV Capital Management bought 1 Royalty Pharma share in Q1 2026, an estimated $44.
Royalty Pharma made up ﹤0.01% of MV Capital Management's portfolio in Q1 2026, its #619 holding.
MV Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 10 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.